Tenet Powers Through Exchange Headwinds with Strong Margin Execution and Raised Guidance

Strong Quarter, Higher Guidance

Tenet Healthcare delivered a second-quarter beat that was as much about execution as about the underlying market. Total net operating revenues reached $5.6 billion, consolidated adjusted EBITDA was $1.304 billion, and adjusted diluted EPS rose 52% to $6.12. Management raised its full-year adjusted EBITDA guidance range by $295 million at the midpoint to $4.83–$5.03 billion, and increased its revenue and free cash flow guidance as well. As CEO Saum Sutaria put it, “We continue to deliver results exceeding our goals based on the fundamental performance of our business.” — Saum Sutaria, CEO or President · 2026-07-24 The beat was broad-based, but the standout was the hospital segment, where adjusted EBITDA grew 22% year over year to $762 million, and adjusted EBITDA margin expanded to 18%.

Cost Initiatives and Margin Expansion

The margin expansion is not a one-off. Sutaria outlined a multi-pronged cost program that goes beyond typical annual efficiency efforts: traditional productivity and contract renegotiations, clinical operations improvements (length-of-stay, emergency department throughput, scheduling), and a deeper push into automation and AI, often executed through the company’s global business center. "We really didn't feel that category one would be adequate to sustain us through the next few years," he said, explaining why they invested in more complex clinical and technology-driven initiatives. “All three of those areas were things that we had planned or spent time planning last year... we were just able to hit the ground running on execution in January.” — Saum Sutaria, CEO or President · 2026-07-24 This fundamental outperformance is tangible: the hospital segment's adjusted EBITDA margin reached 18% in Q2, and management now expects full-year margin strength to persist.

Navigating Exchange Headwinds

The biggest bear case on Tenet has been its exposure to Affordable Care Act exchange enrollment, which is declining as enhanced premium tax credits lapse. Finance chief Sun Park confirmed the magnitude: “Exchange revenues in the quarter were down about 17%. Exchange volume admissions down about 13.5%.” — Sun Park, CFO or Senior Financial Executive · 2026-07-24 The decline represented roughly $65 million of revenue headwind in the quarter. Yet management had anticipated this and flexed costs accordingly. They also received $92 million of favorable out-of-period supplemental Medicaid revenues, though they noted a clean beat even excluding that. The company is watching the exchange enrollment situation closely, particularly in states like Florida, Arizona, Michigan, South Carolina, and Texas. As Sutaria noted during the Q&A, the conversion from exchange patients to uninsured has been near one-to-one, and they expect the erosion to moderate in the back half.

Capital Deployment and Outlook

What really moves the needle for shareholders, though, is capital allocation. Tenet repurchased 5.7 million shares for $1.04 billion in Q2, boosting year-to-date buybacks to $1.36 billion, and the board authorized a further $2 billion increase. The company generated free cash flow (less SBC) of $1.4 billion in the quarter, and management now sees full-year adjusted free cash flow after NCI of $1.825–$2.055 billion. Sun Park pointed to the free cash flow yield as a reason buybacks remain attractive: “Even if when we look at ourselves on a free cash flow yield metric, we feel our shares are still very well discounted based on the free cash flow yield.” — Sun Park, CFO or Senior Financial Executive · 2026-07-24 USPI continues to be the growth engine, with adjusted EBITDA up 9% and a pipeline of M&A that management now expects to exceed $300 million for the year. The balance sheet remains comfortable, with leverage at 2.33x EBITDA (or 2.9x EBITDA less NCI) and no significant debt maturities until late 2027.

This is not an environment to be pessimistic about with respect to the acute care industry... we should continue to be optimistic that if we work on access, if we make it easy for doctors and patients to get in, if the service levels improve, I think the demand is there.

The market has taken note: after a short dip, THC shares are up more than 40% over the past 90 days, recovering strongly. Tenet’s differentiated position — a leading ambulatory surgery franchise, a focused hospital portfolio, and a relentless cost culture — is paying off. As the company raises guidance and deploys capital aggressively, it is proving that it can navigate a challenging payer environment while still delivering outsized returns.